MHS 552
Alternative Names: MHS-552Latest Information Update: 28 Sep 2024
Price :
$50 *
At a glance
- Originator Novartis
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Systemic lupus erythematosus
- No development reported Autoimmune disorders
Most Recent Events
- 28 Sep 2024 No recent reports of development identified for phase-I development in Autoimmune-disorders in Switzerland
- 26 Sep 2023 Novartis Pharmaceuticals terminates phase I clinical trial in Systemic lupus erythematosus in Germany (SC), due to sponsor decision (NCT05203419)
- 05 Apr 2023 Novartis Pharmaceuticals withdraws a phase I trial for Type 1 diabetes mellitus due to sponsors decision (NCT05272059)